|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Departments of Bioimmunotherapy, Cancer
Biology, and Molecular Pathology, University of Texas, M D Anderson
Cancer Center, Houston, TX.
Clinical studies have shown that the tyrosine kinase inhibitor
STI571 effectively controls BCR-ABL-positive chronic myelogenous leukemia (CML). However, disease progression while on STI571 therapy has been reported, suggesting de novo or intrinsic resistance to
BCR-ABL-targeted therapy. To investigate possible mediators of
acquired STI571 resistance, K562 cells resistant to 5 µM STI571 (K562-R) were cloned and compared to the parental cell population. K562-R cells had reduced BCR-ABL expression and limited activation of
BCR-ABL signaling cascades (Stat 5, CrkL, MAPK). STI571 failed to
activate caspase cascades or to suppress expression of survival genes
(bcl-xL) in resistant cells. Gene sequencing and tyrosine kinase
activity measurements demonstrated that K562-R cells retained wild-type
and active BCR-ABL tyrosine kinase that was inhibitable by in vitro
incubation with STI571, suggesting that BCR-ABL was not coupled to
proliferation or survival of K562-R cells. The src-related kinase LYN
was highly overexpressed and activated in K562-R cells, and its
inhibition reduced proliferation and survival of K562-R cells while
having limited effects of K562 cells. Specimens taken from patients
with advanced CML that progressed on STI571 therapy also were analyzed
for LYN kinase expression, and they were found to be elevated to a
level similar to that of K562-R cells. Comparison of samples from
patients taken prior to and following STI571 failure suggested that
expression and/or activation of LYN/HCK occurs during disease
progression. Together, these results suggest that acquired STI571
resistance may be associated with BCR-ABL independence and mediated in
part through overexpression of other tyrosine kinases.
(Blood. 2003;101:690-698) Cytogenetic abnormalities are common in
adult-onset leukemias, and much attention has been focused on
understanding both the cause and consequence of specific
alterations.1 One of the first and most highly
investigated cytogenetic changes is the 9:22 reciprocal chromosomal
translocation in chronic myelogenous and, to a lesser extent, acute
lymphocytic leukemias.1,2 Translocation places the c-abl
gene under the transcriptional control of the bcr locus, allowing
expression of a hybrid protein encoded by 1 to 3 exons of the bcr gene
and all but the first exon of c-abl.3 This chimeric
BCR-ABL protein (p190 or p210) expresses intrinsic tyrosine kinase
activity with altered compartmentalization and distinctions in
substrate accessible when compared to the predominantly nuclear c-abl
protein.4 Tyrosine kinase activity is essential for the
transforming function of BCR-ABL, and expression of BCR-ABL in stem
cells of immune-deficient mice results in altered hematopoiesis
resembling human leukemialike disorders.5,6 These
observations support a role for BCR-ABL in early leukemogenesis and as
a specific target for therapeutic intervention in chronic myelogenous
leukemia (CML).
BCR-ABL expression alters many signaling pathways that increase cell
survival and cell cycle progression.3,7 Many of these
pathways are used by cytokines that regulate hematopoiesis, and
constitutive enforcement of these cascades by BCR-ABL prolongs survival
and provides a proliferative advantage early in
leukemogenesis.8 Altered survival and cell cycle
regulation may promote additional chromosomal alterations and mutations
that parallel or amplify BCR-ABL transformation. These changes may lead
to acceleration of the disease and play a role in the aggressive nature
of late-stage CML. Although many changes have been described in
late-stage disease, some evidence suggests that additional tyrosine
kinases that function downstream of BCR-ABL or are activated in
leukemic blasts (LYN, HCK) contribute to late-stage
disease.9,10
STI571 (Gleevec, imatinib mesylate; Novartis AG, Basel, Switzerland) is
a tyrosine kinase inhibitor, active against BCR-ABL and other specific
kinase targets.11,12 The drug has effective clinical
activity in CML and other BCR-ABL (+) leukemias and has recently been
approved by the Food and Drug Administration for patients with
BCR-ABL(+) leukemia. Patients recently diagnosed (< 1 year ago) or in
early phases of the disease achieve early and stable hematologic
remission with loss of the Philadelphia (Ph) chromosome in some
patients.13 Patients with late-stage disease (accelerated
phase or blast crisis) can achieve hematologic remission but frequently
progress on therapy.11-13 These results suggest that
although BCR-ABL expression is retained, STI571 responsiveness may be
reduced. Several mechanisms have been proposed that account for loss of
effective STI571 therapy in advanced disease, including pharmacologic
barriers or BCR-ABL gene amplification/mutation, as suggested in recent
studies.14-18 Cell model studies of minimally STI571-resistant leukemic cell clones have shown that BCR-ABL overexpression may account for loss of STI571 sensitivity, but other
cell models suggest mechanisms unrelated to changes in BCR-ABL expression.14-18 More mechanistic studies of STI571
resistance are necessary to understand cellular and clinical
responsiveness to STI571.
To define alternate mechanisms of STI571 resistance, K562 erythroid
leukemic cells were selected for high-level resistance to STI571
(IC50 > 5 µM). Protein, signaling, and inhibitor
studies suggest that these cells had become resistant to STI571 through loss of cellular dependence on BCR-ABL and not through mutations or
loss of sensitivity to STI571-mediated kinase inhibition. Growth and
survival in these cells was controlled by overexpression and/or activation of tyrosine kinases that are not inhibited by STI571, and
analysis of clinical specimens support a role for the src-family of
kinases in STI571 resistance and progressive disease. This cell model
predicts that chronic BCR-ABL inhibition may promote outgrowth of
BCR-ABL-independent CML cells, allowing cells to evade STI571-mediated apoptosis.
Cell lines, kinase inhibitors, drugs, and antibodies
Antibodies used in these studies include poly (ADP-ribose) polymerase
(PARP), phosphoMAPK, mitogen-activated protein kinase (MAPK)
(Cell Signaling, Beverly, MA), phosphotyrosine, phosphoSTAT5, CrkL
(Upstate Biotechnology Institute, Lake Placid, NY),
c-abl8E9, c-src (Oncogene Sciences, San Diego, CA),
bcl-xL, LYN, HCK, phosphoHCK (Santa Cruz Biotechnology,
Santa Cruz, CA), and actin (Sigma, St Louis, MO). Polyclonal anti-STAT5
(a/b) was kindly provided by Dr Robert Kirken (University of Texas,
Health Science Center, Houston, TX).
Isolation of STI571-resistant K562 cells
Apoptosis and cell survival measurement PARP cleavage was used as a measure of apoptosis and was examined in cell lysates by immunoblotting, as previously described.19,24 Methyl-thiazol tetrazolium (MTT) assays were performed as previously described to quantitate changes in cell proliferation/survival.19Analysis of kinase expression and signal transduction Protein levels of BCR-ABL, Stat 5, LYN, HCK, and phosphotyrosine were compared between parental and resistant cells by immunoblotting equal protein cell lysates (determined by bicinchoninic acid protein assay [BCA], Pierce Chemical, Rockford, IL) with specific antibodies. Antibodies against phosphorylated (activated) forms of signaling intermediates also were used to analyze changes in BCR-ABL signaling (Stat 5, MAPK) and other tyrosine kinases (phosphoHCK, HCK, LYN). CrkL was immunoprecipitated from cell lysates (see "Immune complex tyrosine kinase activity assay"), resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotted with anti-p-Tyr to examine its tyrosine phosphorylation. The blot was stripped of primary antibody and reblotted with anti-CrkL to determine its relative expression and recovery by immunoprecipitation. All immunoblots were developed with horseradish-peroxidase-conjugated secondary antibodies (BioRad Laboratories, Hercules, CA) and enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia, Arlington Heights, IL).Immune complex tyrosine kinase activity assay K562 and K562-R cell lysates (400 µg in lysis buffer; as described by Donato and Perez24) were incubated with 2 µg of antibody against c-abl, LYN or HCK (2 hours), and protein A/G-sepharose (40 µL; 50% slurry, 1 hour). Immune complexes were washed (with lysis buffer), and tyrosine kinase activity was measured in immune complexes by resuspension in kinase buffer consisting of 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), pH 7.5, 10 mM MnCl2, 0.1 mM Na2VO4, and 10 µg enolase, as previously described.25 Kinase inhibitors (at the concentrations indicated) were preincubated with immune complexes for 30 minutes in some assays. Kinase reactions were initiated by the addition of 10 µCi (0.37 MBq) [32P]-adenosine triphosphate ([32P]-ATP) in a total volume of 50 µL and were incubated for 30 minutes at room temperature. Kinase reactions were quenched by the addition of SDS sample buffer, and after heating to 100°C for 5 minutes reactions were resolved by SDS-PAGE. Phosphoproteins were detected by autoradiography and quantitated by PhosphorImager (Molecular Dynamics, Sunnyvale, CA).RT-PCR amplification of BCR-ABL and sequencing of the ABL kinase domain For bcr-abl reverse transcription-polymerase chain reaction (RT-PCR), mRNA was isolated as described below. RT-PCR reactions were performed in a 50 µL volume using SuperScript One-Step RT-PCR with Platinum Taq from Invitrogen (Carlsbad, CA). Reagents were at the following final concentrations: 1 × reaction mix, 1 µg total RNA, 0.2 µM sense primer, 0.2 µM antisense primer, 4 mM MgSO4, and 2 units RT/Platinum Taq mix. RT-PCR was performed on an MJ Research PTC-200 DNA Engine (Waltham, MA) as follows: for cDNA synthesis, 30 minutes at 55°C followed by 2 minutes at 94°C; for PCR, 40 cycles of 94°C for 15 seconds, 59°C for 30 seconds, and 72°C for 80 seconds. Reactions were run on a 1% agarose gel, and the 1.3-kb bcr-abl bands were excised, purified, and eluted in a 30 µL volume using a gel extraction kit from Qiagen (Valencia, CA). Platinum Taq DNA polymerase was used for nested PCR amplification of the abl kinase domain of the 1.3-kb bcr-abl PCR product. Reaction components were 1 × PCR buffer, 0.2 mM each dNTP, 1.5 mM MgCl2, 0.2 µM sense primer, 0.2 µM antisense), 5 µL of the eluted DNA from above, and 2.5 units of platinum Taq. PCR was performed on an MJ Research PTC-200 DNA Engine as follows: 1 cycle of 94°C for 2 minutes and 30 cycles of 94°C for 15 seconds, 56°C for 30 seconds, and 72°C for 30 seconds. Reaction products were purified as above and sequenced on a Biomeck 3700 automated DNA sequencer (Applied Biosystems, Foster City, CA). Primers were obtained from Sigma-Genosys (The Woodlands, TX), and the sequences used were as follows: forward: 5'-gaagcttctccctggcatcccgt-3' and reverse 5'-gccaggctctcgggtgcagtcc-3'; for amplification of a 1.3-kb bcr-abl product representing the BCR-ABL junction and kinase domain. For nested PCR of the 323-bp kinase domain: forward: 5'-gcgcaacaagcccactgtctatgg-3' and reverse 5'-gtagtccaggaggttcccgt-3'.Lyn and BCR-ABL Northern blot K562 cell RNA was extracted with Trizol reagent as previously described.26 For Northern blot, 15 µg total RNA was separated on a formaldehyde gel and transferred to a Schleicher and Schuell nylon membrane (Keene, NH) using standard protocols. The membrane was probed with 20 ng/µL of a biotinylated 1.3-kb bcr-abl PCR amplification product (as described in "RT-PCR amplification of BCR-ABL and sequencing of the ABL kinase domain") or a biotinylated lyn probe using New England Biolabs' NEBlot Phototope Kit (Beverly, MA) according to the standard hybridization protocol. The template for the lyn probe was a lyn insert separated from the pcDNA3-HA-lyn vector, kindly provided by Dr Seth Corey (University of Pittsburgh, Pittsburgh, PA). The probe was detected using the maximum sensitivity protocol from New England Biolabs' Phototope-Star detection kit.LYN antisense treatment Phosphorothioate antisense oligodeoxynucleotide LYN sequence (Lyn-AS), as previously described,27,28 and a sense oligomer representing the first 7 codons of the LYN gene (Lyn S1; complementary to Lyn-AS) were used in these studies (Sigma-Genosys). To examine cellular effects of oligomers, 20 000 cells growing in 96-well plates in RMPI 1640 media with 10% fetal bovine serum were treated with 20 µM oligomer for 24 hours. Cell media were supplemented with 5 µM oligomers for an additional 48 hours before cell growth and survival were estimated by MTT assays as described above. To monitor effects on LYN expression, cells were treated with 10 µM oligomer for 24 hours and supplemented with the same concentration for an additional 48 hours before lysates were prepared as described above. Equal protein (40 µg) cell lysates were resolved and immunoblotted with anti-LYN or antiactin as a protein loading control.Analysis of LYN expression in specimens from STI571-treated CML patients Blood samples were taken from accelerated-phase and blast-crisis CML patients prior to and during treatment with STI571 and, in some cases, during disease progression but before drug withdrawal. Single specimens from CML patients that had measurable hematologic responses to STI571 but subsequently progressed on therapy were also collected prior to withdrawal from STI571. All patients received 400 to 600 mg STI571 daily. All studies involving human subjects were approved by the Internal Review Board of M D Anderson Cancer Center, and informed consent was obtained from each patient prior to initiation of this procedure.Briefly, fresh peripheral blood (~ 18 mL) was overlaid onto Histopaque-1077 (Sigma) and centrifuged at 400g for 15 minutes. The cells at interphase were removed by aspiration and washed once with phosphate buffered saline. Cell preparations containing significant red blood cell contamination were subjected to treatment with ammonium chloride potassium (ACK) lysis buffer (0.154 M ammonium chloride, 0.01 M KHCO3, 0.13 µM EDTA [ethylenediaminetetraacetic acid]) for 30 minutes. Remaining cells were lysed in solubilization buffer (as described above) for 30 minutes on ice, and lysates were clarified by centrifugation at 12 000g (4°C) for 15 minutes. The supernatant fractions were retained, and protein content was measured by BCA protein dye reagent (Pierce). Next, 20 µg protein were resolved by SDS-PAGE (8% acrylamide), transferred to nitrocellulose membranes, and immunoblotted with anti-phosphoHCK, anti-HCK, or anti-LYN (Santa Cruz Biotechnology). The antigen was detected with secondary antibody and ECL reagent as described above. After primary antigen detection, the membrane was stripped and reprobed with antiactin to determine the relative protein load in each lane.
To examine potential mechanisms of acquired STI571 resistance,
K562 cells were cloned in the presence of 5 µM STI571, and stable
clones were compared to the parental population for STI571 responsiveness. As shown in Figure 1A,
parental K562 cell responsiveness is detected at nM concentrations of
STI571 (IC50 ~ 0.1 µM), while 10 µM STI571
failed to reduce K562-R cell survival or proliferation. These cells
expressed equal sensitivity to doxorubicin (Figure 1B), demonstrating
defects in STI571 responsiveness that were not mediated by expression
of multidrug resistance genes29 or global changes in
responsiveness to an apoptotic stimulus. Because previous studies
suggested that changes in BCR-ABL expression and mutations in the
kinase domain correlate with STI571 responsiveness in resistant
cells,14,15,17,18 BCR-ABL expression, signaling, and gene
mutations were examined in K562 and K562-R cells. As shown in Figure
2, BCR-ABL mRNA, protein expression, and
signaling (Stat5, MAPK, CrkL) were reduced in resistant cells.
Sequencing of the nested PCR product derived from a 1.3-kb BCR-ABL
RT-PCR template (as described in "Materials and methods") failed to
detect mutations in the abl kinase domain (codons 225-328) of K562-R cells. To confirmed wild-type BCR-ABL tyrosine kinase activity in
resistant cells, immune complex kinase assays of BCR-ABL
immunoprecipitates were performed. As shown in Figure
3, BCR-ABL tyrosine kinase activity was
measurable in both parental and resistant cells, and incubation with
STI571 reduced BCR-ABL tyrosine kinase activity and substrate (enolase)
phosphorylation. This analysis suggested that STI571 resistance was not
due to overexpression or mutations affecting STI571 binding in K562-R
cells. Further, down-regulation and inhibition of BCR-ABL were not
associated with an STI571 antiproliferative response in these cells.
Although tyrosine phosphoprotein levels were reduced in resistant
cells, a tyrosine phosphoprotein of ~60 kDa was highly expressed in
K562-R cells (Figure 2). Several techniques were used to identify this
protein and to define its role in K562-R cells.
As previously described, STI571 induces apoptosis through inhibition of
BCR-ABL-mediated tyrosine phosphorylation, changes in survival gene
expression, and activation of caspase cascades.19 As shown
in Figure 4, STI571 reduced tyrosine
phosphorylation and bcl-xL expression, and it induced PARP cleavage in
K562 cells but failed to affect these changes in K562-R
cells.19 However, a tyrosine kinase inhibitor with
reported activity against both src-family and abl kinases (PD180970)
reduced tyrosine phosphorylation in both K562 and K562-R
cells.20,30 Tyrosine phosphorylation of the p60
phosphoprotein was partially reduced by PD180970 in K562-R cells
(Figure 4), suggesting a relationship to src-family kinases or kinase
substrates. PD180970 induced PARP cleavage and growth inhibition in
both STI571-sensitive and -resistant K562 cells (Figure
5A-B), and inhibitors with specificity
for src kinases (PP2) induced greater antiproliferative and apoptotic
effects on K562-R cells (Figure 5C). These results suggested that
expression or activation of a src-family kinase in K562-R plays a role
in STI571 resistance.
Previous studies demonstrated that specific members of the src kinase
family, such as HCK and LYN, are expressed and activated in leukemic
blasts.9 Additional studies demonstrated that these kinases (HCK, LYN) are activated by BCR-ABL kinase,10 and
HCK appears to play an important role in BCR-ABL-mediated cytokine independence.31 Immunodepletion of K562-R cell lysates
demonstrated that anti-LYN but not anti-HCK reduced p60 recovery in
cell supernatants, confirmed by the loss of LYN from depleted lysates
(Figure 6). K562-R cell LYN protein and
mRNA expression were increased 4- to 8-fold, respectively, when
compared to K562 cells (Figure 6B-C). As shown in Figure 6D,
overexpression of LYN in K562-R cells correlated with a 7-fold increase
in LYN tyrosine kinase activity when examined in immune complex kinase
assays with exogenous substrate (enolase). HCK immune complexes from
either K562 or K562-R cells had no detectable tyrosine kinase activity,
demonstrating a specific increase in LYN expression and tyrosine kinase
activity in STI571-resistant K562-R cells. From these results, we
concluded that the p60 tyrosyl-phosphoprotein in STI571-resistant K562
cells is overexpressed LYN kinase.
To determine whether LYN kinase plays a role in K562-R cell growth and
survival, LYN kinase activity or expression was suppressed by
incubation with src-family kinase-specific inhibitor or LYN antisense,
respectively. CGP-76030 (Novartis AG) is representative of a class of
substituted 5,7-diphenyl-pyrrolo [2,3d]pyrimidines previously shown
to inhibit src activity in vitro and to effect osteoclastic activity in
animal models.21,22 The specificity of this compound was
tested in BCR-ABL or LYN immune-complexes from K562 or K562-R cells. As
shown in Figure 7, CGP-76030 inhibited LYN kinase activity from both K562 and K562-R cells with nM
sensitivity. Dose-dependent LYN kinase inhibition was measurable in
K562-R cell-derived immune complexes. However, incubation of BCR-ABL immune complexes with CGP-76030 at LYN inhibitory concentrations had
limited BCR-ABL tyrosine kinase inhibitory affects. Similar results
were obtained with immune complexes derived from K562 cells. These
results demonstrate that CGP-76030 has greater LYN kinase inhibitory
activity when compared to BCR-ABL in vitro. Distinctions in LYN kinase
inhibition by CGP-76030 in immune complexes and intact cells may be due
to the cellular ATP content that can reduce efficacy of kinase
inhibition.
The effects of CGP-76030 on LYN kinase phosphorylation (activation),
growth, and apoptosis were examined in K562-R cells. As shown in Figure
8A, CGP-76030 reduced LYN tyrosine
phosphorylation at a site previously shown to be involved in its
autophosphorylation/activation (Y508; Porter et al32) and
induced PARP proteolysis after extended inhibition of tyrosine kinase
activity (> 12 hours). CGP-76030 treatment resulted in greater
antiproliferative effects on K562-R cells than that measured in K562
cells. As shown in Figure 8B, CGP-76030 at 1.25 µM and lower
concentrations had greater inhibitory effects on K562-R cells
than parental STI571-sensitive K562 cells. Inhibitors of other protein
kinases (50 µM AG-490, 50 µM LY298002) previously shown to play a
role in leukemic cell growth and survival (Janus kinase 2 [Jak 2];
Wilson-Rawls et al33; phosphatidylinositol-3'-kinase, Neshat et al34) failed to induce apoptosis or reduce
proliferation of K562 or K562-R cells by more than 50% (data not
shown). Together with the in vitro effects of CGP-76030, these
data provide evidence of a role for LYN in K562-R cell growth
and survival.
To confirm a role for LYN expression in K562-R cell growth and
survival, the effects of LYN antisense (LYN-AS) oligonucleotide incubation were examined and compared to STI571-sensitive K562 cells.
Incubation with LYN-AS reduced LYN expression by ~ 50% in both
K562 and K562-R cells (Figure 9), while
LYN sense oligomers (LYN-S) had little effect of LYN expression.
Importantly, LYN-AS significantly reduced K562-R cell growth (~ 50% reduction) while having limited effects on K562 cells. In
contrast, LYN-S had only minimal effects on growth of either
population. Together, these results suggest that LYN expression plays a
significant growth regulatory role in K562-R cells.
CML blast-crisis patients frequently progress on STI571 therapy, and
clinical studies suggest that progression may be related to STI571
resistance.13,14,18 Resistance can be mediated by mutations within the ATP binding site in the abl kinase
domain.14 However, other mechanisms may also play a role
in progressive disease.16,18 Based on the K562 cell model,
increased expression of src-family kinases may play a role in acquired
STI571 resistance. To examine this possibility, CML samples from
blast-crisis patients who progressed on STI571 (400-600 mg doses;
progression within 3 months) were subjected to immunoblot and compared
to K562-R cells for LYN and HCK expression. Samples were collected from relapsing patients prior to discontinuing STI571 therapy. As shown in
Figure 10A, LYN kinase alone or LYN and
HCK expression was detected in all samples tested. Expression levels in
all samples were similar to those detected in K562-R cells (lane 1). To
determine whether these changes correlated with disease progression,
clinical samples were taken from blast-crisis patients prior to
initiation of STI571 therapy. These samples were compared to specimens
from the same patient after disease progression on therapy (49 to 186 days of STI571 therapy). Myeloblast contents varied by no more than
25% in these samples. As shown in Figure 10B, a moderate increase in LYN expression (and activation) was detected in patient A, while more
significant changes in LYN (and HCK) were detected in patient B. Increased expression correlated with activation of these kinases when
monitored by immunoblotting with LYN/HCK activation-specific antibody
(p-HCK, p-LYN). These results suggest that src-family kinases are
highly expressed and activated in CML blast-crisis patients and their
increased expression correlates with progressive disease or STI571
resistance in some CML patients. Based on in vitro studies of K562
cells, the results also suggest that chronic STI571 exposure may induce
expression or activation of other tyrosine kinases (that are unaffected
by STI571), which contribute to BCR-ABL-independent growth and STI571
resistance.
STI571 has demonstrated remarkable clinical activity in CML, but chronic use of this inhibitor may result in reduced efficacy, STI571 resistance, and disease progression. Clinical trials with STI571 have shown that blast-crisis patients frequently progress within 3 to 6 months of treatment, suggesting that BCR-ABL inhibition is not sufficient to prevent disease progression or to restrict clonal expansion of resistant cells.35 The underlying mechanisms of STI571 resistance and clonal expansion are not fully understood. Clinical samples from resistant patients suggest that CML cells retain expression of BCR-ABL and dependence on its downstream signaling for sustained growth and survival. BCR-ABL is overexpressed or is unaffected by STI571 due to BCR-ABL point mutations or increased drug efflux, allowing cells to escape STI571-mediated apoptosis and growth inhibition. However, cells expressing BCR-ABL mutations do not appear to predominate in CML patients because high-sensitivity procedures (nested PCR) are required to detect gene mutations.14,36-38 Even with high-sensitivity detection techniques, only a limited percentage of resistant patients express detectable BCR-ABL gene mutations, suggesting other resistance mechanism exist. The results presented in this report suggest that acquired resistance to STI571 is not associated with drug resistance mechanisms or mutations in the BCR-ABL gene but may be a consequence of expansion of BCR-ABL-independent cells. K562-R cells express wild-type BCR-ABL based on sequence analysis (kinase domain) and in vitro kinase measurements. Immune complex kinase assays demonstrated comparable BCR-ABL tyrosine kinase activity in extracts from both K562 and K562-R cells, which was inhibited by in vitro incubation with STI571. Together with other characteristics of K562-R cells (reduced BCR-ABL expression and downstream signaling), these results suggest that BCR-ABL inhibition is not linked to STI571-resistant cell apoptosis. This is aligned with the observed loss of constitutive Stat5 or MAPK activation in K562-R, previously shown to be important contributors to BCR-ABL-mediated transformation.19,39-41 The results presented in Figures 2 and 4 demonstrate that through a reduction in BCR-ABL expression and reduced signaling through chronic STI571 inhibition, K562-R cells are no longer BCR-ABL kinase or BCR-ABL signaling dependent. Expression of the src-related LYN kinase may play a role in acquisition of BCR-ABL independence. This phenotype is rare when compared to other cell models of STI571 resistance, which frequently report increased BCR-ABL expression and signaling activity. Our other cell models (Mo7e, BV-173) did not achieve complete STI571 resistance but rather a 2- to 3-fold shift in STI571 sensitivity and a corresponding increase in BCR-ABL expression (data not shown). Due to its unique characteristics, the K562-R variant was the focus of this report. LYN kinase previously has been shown to be an important component in cytokine signal transduction in a variety of cell types and is reported to play a key role in the growth and apoptotic regulation of hematopoietic cells.42,43 In K562-R cells, overexpression and activation of LYN kinase appear to play a dominant role in their proliferation and survival. This conclusion is based on studies with kinase inhibitors, which were previously reported to target src kinases (PP2) or to inhibit both abl and src kinases (PD180970) in BCR-ABL-expressing cells.20 Growth inhibition and apoptotic studies demonstrate that targeting both kinase families overcomes apoptotic resistance in K562-R cells, while src-selective inhibitors show a consistently greater inhibitory effect on K562-R cells when compared to the parental population. A novel src inhibitory compound (CGP-76030; Missbach et al21,22) was shown to dose-dependently inhibit LYN kinase activity in vitro without significant affects on BCR-ABL (Figure 7). Selective inhibition of LYN in K562-R cells with CGP-76030 may explain their increased sensitivity to this compound when compared to K562 wild-type cells. We have been unable to detect cellular affects of CGP-76030 on LYN phosphorylation in parental K562 cells, perhaps due to its low level of expression and activation in this cell line. However, despite low expression levels, inhibition of LYN kinase activity by CGP-76030 in K562 cells only has limited affects on the growth of these cells when compared to the K562-R cell line (Figure 8). These observations suggest a shift induced through chronic STI571 exposure from BCR-ABL to LYN kinase dependence in STI571-resistant K562-R cells. In support of this conclusion, we also demonstrated that although LYN was expressed at considerably higher levels in K562-R cells, antisense oligonucleotides that suppress LYN expression had greater inhibitory effects on K562-R cells when compared to the K562 parental population (Figure 9). These results further support a role for LYN kinase in the growth and apoptotic protection of STI571-resistant K562-R cells. Of significance to these studies, both LYN and the related HCK kinase
have been shown to be activated by BCR-ABL,9,10 and some
studies suggest that HCK activity is essential for cytokine independence of BCR-ABL-expressing cells.31 However, LYN
and HCK kinase also may be activated through other mechanisms, as shown
in studies of blasts from acute leukemias.9 LYN kinase activity appears to be essential for signal transduction of stress kinase pathways and tyrosine phosphorylation of proteins involved in
DNA repair or damage recognition.44,45 Thus, LYN
overexpression and activation in STI571-resistant cells are likely to
promote growth and apoptotic protection through a signaling cascade
that is distinct from that of BCR-ABL. These pathways are currently being examined, but initial studies have failed to detect a role for
nuclear factor- LYN overexpression also was detected in lysates from STI571-resistant CML patients. However, other STI571-resistant mechanisms, including BCR-ABL mutations, also may exist. Prior to evaluating LYN expression in clinical specimens from these patients (progressed within 3 to 6 months of STI571 therapy), BCR-ABL T315 mutations (using the nested PCR restriction digest analysis as previously reported; Gorre et al14) were analyzed but none were detected. Further sequence analysis of the kinase domain in 4 specimens demonstrated only wild-type BCR-ABL expression (data not shown) and the possible existence of other resistance mechanisms in these patients. In 2 patients where clinical specimens were obtained prior to STI571 therapy, the effects on LYN expression and activation as patients progressed were evaluated. Changes in LYN and HCK expression and activation were detected in both patients with marked increased expression in patient B (Figure 10B). While it is unclear whether expression and/or activation of src kinases are sufficient to confer STI571 resistance in clinical samples, these results support evidence of a role for this kinase family in late-stage disease and BCR-ABL autonomous growth. Targeting both the abl and src kinases in late-stage patients may reduce disease progression and prevent acquired resistance to STI571. As shown in Figure 10, altered signaling pathways, such as LYN, may be engaged in CML cells as a compensatory response to potent or chronic BCR-ABL inhibition. From the current study, it is hypothesized that CML cells may toggle between BCR-ABL and LYN dependence as a means of reducing susceptibility to STI571-induced growth arrest and apoptosis. Each of these kinases appear to signal through independent downstream cascades, providing an exploitable means of evaluating shifts in BCR-ABL dependence in clinical specimens. However, the appropriate signaling pathways engaged by LYN (or related kinases) first must be defined and are currently under investigation. Lineage-specific expression of other tyrosine kinases (such as BTK in acute lymphocytic leukemia patients) may play a parallel role in reducing BCR-ABL dependence and reducing STI571 efficacy in other Ph(+) leukemias.47 Overall, the results presented in this report suggest that STI571 resistance in K562 cells is mediated through BCR-ABL independent activation and overexpression of LYN. Tyrosine kinases with distinct ATP binding pockets that are not accessible to STI571 (such as those of the src family) may underlie development of BCR-ABL independence in some CML cells. Targeted inhibition of LYN kinase may circumvent STI571 resistance and disease progression in CML. Additional studies of BCR-ABL independence and secondary signaling events in STI571-resistant patient-derived cell lines will improve our understanding and therapy for advanced-stage CML.
Submitted November 8, 2001; accepted September 13, 2002.
Supported by a grant from the Leukemia Society of America (6153-02 [N.J.D.]).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nicholas J. Donato, Department of Bioimmunotherapy, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 422, Houston, TX 77030; e-mail: ndonato{at}mdanderson.org.
1. Sawyers CL. Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Leuk Res. 1988;22:1113-1122. 2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990-998[Medline] [Order article via Infotrieve].
3.
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
The biology of chronic myeloid leukemia.
N Engl J Med.
1999;341:164-172 4. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta. 1997;1333:F201-F216[Medline] [Order article via Infotrieve].
5.
Daley GQ, Van Etten RA, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830
6.
Era T, Witte ON.
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Proc Natl Acad Sci U S A.
2000;97:1737-1742 7. Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001;73:278-291[Medline] [Order article via Infotrieve].
8.
Nieborowska-Skorska M, Wasik MA, Slupianek A, et al.
Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 andSH2 domains of BCR/ABL and is required for leukemogenesis.
J Exp Med.
1999;189:1229-1242 9. Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. 1999;13:855-861[CrossRef][Medline] [Order article via Infotrieve].
10.
Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M.
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Cancer Res.
1996;56:3589-3596
11.
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037 12. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta. 2001;1551:M11-M28[Medline] [Order article via Infotrieve].
13.
O'Dwyer ME, Druker BJ.
Chronic myelogenous leukaemia
14.
Gorre ME, Mohammed M, Ellwood K, et al.
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science.
2001;293:876-880
15.
le Coutre P, Tassi E, Varella-Garcia M, et al.
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
Blood.
2000;95:1758-1766
16.
Gambacorti-Passerini C, Barni R, le Coutre P, et al.
Role of 1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571.
J Natl Cancer Inst.
2000;92:1641-1650
17.
Mahon FX, Deininger MW, Schultheis B, et al.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood.
2000;96:1070-1079
18.
Weisberg E, Griffin JD.
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
Blood.
2000;95:3498-3505
19.
Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M.
Down-regulation of interleukin-3/granulocyte-macrophagecolony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
Blood.
2001;97:2846-2853
20.
Dorsey JF, Jove R, Kraker AJ, Wu J.
The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abltyrosine kinase and induces apoptosis of K562 leukemic cells.
Cancer Res.
2000;60:3127-3131 21. Missbach M, Altmann E, Widler L. Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000;10:945-949[CrossRef][Medline] [Order article via Infotrieve]. 22. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999;24:437-449[Medline] [Order article via Infotrieve].
23.
Hanke JH, Gardner JP, Dow RL, et al.
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor: study of Lck- and FynT-dependent T cell activation.
J Biol Chem.
1996;271:695-701
24.
Donato NJ, Perez M.
Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells.
J Biol Chem.
1998;273:5067-5072 25. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest. 1993;91:53-60[Medline] [Order article via Infotrieve].
26.
Wang Y, Liu J, Wu Y, et al.
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Cancer Res.
2001;61:138-144
27.
Ishikawa H, Tsuyama N, Abroun S, et al.
Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6.
Blood.
2002;99:2172-2178
28.
Scheuermann RH, Racila E, Tucker T, et al.
Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.
Proc Natl Acad Sci U S A.
1994;91:4048-4052 29. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia. 1993;7:825-831[Medline] [Order article via Infotrieve]. 30. Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, Pledger WJ. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene. 2000;19:2075-2085[CrossRef][Medline] [Order article via Infotrieve].
31.
Lionberger JM, Wilson MB, Smithgall TE.
Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck.
J Biol Chem.
2000;275:18581-18585
32.
Porter M, Schindler T, Kuriyan J, Miller WT.
Reciprocal regulation of Hck activity by phosphorylation of Tyr(527) and Tyr(416): effect of introducing a high affinity intramolecular SH2 ligand.
J Biol Chem.
2000;275:2721-2726
33.
Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB.
P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
Cancer Res.
1996;56:3426-3430
34.
Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL.
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.
Mol Cell Biol.
2000;20:1179-1186
35.
Sawyers CL, Hochhaus A, Feldman E, et al.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blood.
2002;99:3530-3539
36.
Branford S, Rudzki Z, Walsh S, et al.
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Blood.
2002;99:3472-3475
37.
Hofmann W-K, Jones LC, Lemp NA, et al.
Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Blood.
2002;99:1860-1862 38. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359:487-491[CrossRef][Medline] [Order article via Infotrieve].
39.
Horita M, Andreu EJ, Benito A, et al.
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
J Exp Med.
2000;191:977-984
40.
Sonoyama J, Matsumura I, Ezoe S, et al.
Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells.
J Biol Chem.
2002;277:8076-8082
41.
de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L.
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
Blood.
1999;94:1108-1112
42.
Corey SJ, Dombrosky-Ferlan PM, Zuo S, et al.
Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor.
J Biol Chem.
1998;273:3230-3235 43. Grishin A, Sinha S, Roginskaya V, et al. Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF. Oncogene. 2000;19:97-105[CrossRef][Medline] [Order article via Infotrieve].
44.
Grishin AV, Azhipa O, Semenov I, Corey SJ.
Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn negatively regulates genotoxic apoptosis.
Proc Natl Acad Sci U S A.
2001;98:10172-10177
45.
Yoshida K, Weichselbaum R, Kharbanda S, Kufe D.
Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage.
Mol Cell Biol.
2000;20:5370-5380
46.
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J.
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Science.
2000;289:1938-1942 47. Wolf-K Hofmann, Sven de Vos, David Elashoff, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet. 2002;359:481-486[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  R. J. Garg, H. Kantarjian, S. O'Brien, A. Quintas-Cardama, S. Faderl, Z. Estrov, and J. Cortes The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up Blood, November 12, 2009; 114(20): 4361 - 4368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. Agarwal, N. M. Shaik, C. Chen, Z. Yang, and W. F. Elmquist P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 956 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Zhang, J. E. Cortes, H. Yao, L. Zhang, N. G. Reddy, E. Jabbour, H. M. Kantarjian, and D. Jones Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance J. Clin. Oncol., August 1, 2009; 27(22): 3642 - 3649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Apperley, J. E. Cortes, D.-W. Kim, L. Roy, G. J. Roboz, G. Rosti, E. O. Bullorsky, E. Abruzzese, A. Hochhaus, D. Heim, et al. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial J. Clin. Oncol., July 20, 2009; 27(21): 3472 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grosso, A. Puissant, M. Dufies, P. Colosetti, A. Jacquel, K. Lebrigand, P. Barbry, M. Deckert, J. P. Cassuto, B. Mari, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors Mol. Cancer Ther., July 1, 2009; 8(7): 1924 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Eley, F. R. Luo, S. Agrawal, A. Sanil, J. Manning, T. Li, A. Blackwood-Chirchir, and R. Bertz Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects J. Clin. Pharmacol., June 1, 2009; 49(6): 700 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kominsky, J. Klawitter, J. L. Brown, L. G. Boros, J. V. Melo, S. G. Eckhardt, and N. J. Serkova Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells Clin. Cancer Res., May 15, 2009; 15(10): 3442 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-F. Wong Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 17 - 27. [Abstract] [PDF]
|
|
|
|
|
|
X. Shi, Y. Jin, C. Cheng, H. Zhang, W. Zou, Q. Zheng, Z. Lu, Q. Chen, Y. Lai, and J. Pan Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation Clin. Cancer Res., March 1, 2009; 15(5): 1686 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quintas-Cardama and J. Cortes Molecular biology of bcr-abl1-positive chronic myeloid leukemia Blood, February 19, 2009; 113(8): 1619 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Williams, I. S. Lucet, S. P. Klinken, E. Ingley, and J. Rossjohn Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State J. Biol. Chem., January 2, 2009; 284(1): 284 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Blood, December 15, 2008; 112(13): 4839 - 4842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Konig, M. Copland, S. Chu, R. Jove, T. L. Holyoake, and R. Bhatia Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells Cancer Res., December 1, 2008; 68(23): 9624 - 9633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-X. Mahon, S. Hayette, V. Lagarde, F. Belloc, B. Turcq, F. Nicolini, C. Belanger, P. W. Manley, C. Leroy, G. Etienne, et al. Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression Cancer Res., December 1, 2008; 68(23): 9809 - 9816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Lee, W. Ma, X. Zhang, F. Giles, J. Cortes, H. Kantarjian, and M. Albitar BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations Mol. Cancer Ther., December 1, 2008; 7(12): 3834 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Okabe, T. Tauchi, and K. Ohyashiki Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells Clin. Cancer Res., October 1, 2008; 14(19): 6181 - 6186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Porkka, P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, R. Smykla, R. Wild, R. Luo, M. Arnan, B. Brethon, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood, August 15, 2008; 112(4): 1005 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate Blood, August 1, 2008; 112(3): 793 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wu, F. Meng, L.-Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, et al. Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase J Natl Cancer Inst, July 2, 2008; 100(13): 926 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. Deininger Persistent LYN Signaling in Imatinib-Resistant, BCR-ABL-Independent Chronic Myelogenous Leukemia J Natl Cancer Inst, July 2, 2008; 100(13): 908 - 909. [Full Text] [PDF]
|
|
|
|
|
|
H. Guan, Z. Zhou, G. E. Gallick, S.-F. Jia, J. Morales, A. K. Sood, S. J. Corey, and E. S. Kleinerman Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma Mol. Cancer Ther., July 1, 2008; 7(7): 1807 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Montagut, S. V. Sharma, T. Shioda, U. McDermott, M. Ulman, L. E. Ulkus, D. Dias-Santagata, H. Stubbs, D. Y. Lee, A. Singh, et al. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma Cancer Res., June 15, 2008; 68(12): 4853 - 4861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Puissant, S. Grosso, A. Jacquel, N. Belhacene, P. Colosetti, J.-P. Cassuto, and P. Auberger Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol FASEB J, June 1, 2008; 22(6): 1894 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ramirez and J. F. DiPersio Therapy Options in Imatinib Failures Oncologist, April 1, 2008; 13(4): 424 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wu, F. Meng, H. Lu, L. Kong, W. Bornmann, Z. Peng, M. Talpaz, and N. J. Donato Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood, April 1, 2008; 111(7): 3821 - 3829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Carayol, E. Katsoulidis, A. Sassano, J. K. Altman, B. J. Druker, and L. C. Platanias Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway J. Biol. Chem., March 28, 2008; 283(13): 8601 - 8610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ban, Y. Gao, H. M. Amin, A. Howard, C. Miller, Q. Lin, X. Leng, M. Munsell, M. Bar-Eli, R. B. Arlinghaus, et al. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia Blood, March 1, 2008; 111(5): 2904 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Marshall and J. M Hammond Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia Ann. Pharmacother., February 1, 2008; 42(2): 259 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Melo and C. Chuah Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond Hematology, January 1, 2008; 2008(1): 427 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Rix, O. Hantschel, G. Durnberger, L. L. Remsing Rix, M. Planyavsky, N. V. Fernbach, I. Kaupe, K. L. Bennett, P. Valent, J. Colinge, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood, December 1, 2007; 110(12): 4055 - 4063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, E. Jabbour, H. Kantarjian, C. C. Yin, J. Shan, S. O'Brien, G. Garcia-Manero, F. Giles, M. Breeden, N. Reeves, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood, December 1, 2007; 110(12): 4005 - 4011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. A. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, A. M. Apanovitch, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood, October 1, 2007; 110(7): 2309 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rahmani, T. K. Nguyen, P. Dent, and S. Grant The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation Mol. Pharmacol., September 1, 2007; 72(3): 788 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Modi, T. McDonald, S. Chu, J.-K. Yee, S. J. Forman, and R. Bhatia Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells Blood, June 15, 2007; 109(12): 5411 - 5421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science, May 18, 2007; 316(5827): 1039 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guilhot, J. Apperley, D.-W. Kim, E. O. Bullorsky, M. Baccarani, G. J. Roboz, S. Amadori, C. A. de Souza, J. H. Lipton, A. Hochhaus, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood, May 15, 2007; 109(10): 4143 - 4150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tringali, B. Lupo, L. Anastasia, N. Papini, E. Monti, R. Bresciani, G. Tettamanti, and B. Venerando Expression of Sialidase Neu2 in Leukemic K562 Cells Induces Apoptosis by Impairing Bcr-Abl/Src Kinases Signaling J. Biol. Chem., May 11, 2007; 282(19): 14364 - 14372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nguyen, M. Rahmani, H. Harada, P. Dent, and S. Grant MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 Blood, May 1, 2007; 109(9): 4006 - 4015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, P. Rousselot, D.-W. Kim, E. Ritchie, N. Hamerschlak, S. Coutre, A. Hochhaus, F. Guilhot, G. Saglio, J. Apperley, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood, April 15, 2007; 109(8): 3207 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.-A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood, April 15, 2007; 109(8): 3496 - 3499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Bartholomeusz, M. Talpaz, V. Kapuria, L. Y. Kong, S. Wang, Z. Estrov, W. Priebe, J. Wu, and N. J. Donato Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells Blood, April 15, 2007; 109(8): 3470 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hochhaus, H. M. Kantarjian, M. Baccarani, J. H. Lipton, J. F. Apperley, B. J. Druker, T. Facon, S. L. Goldberg, F. Cervantes, D. Niederwieser, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood, March 15, 2007; 109(6): 2303 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, D. Cai, C. Brendel, C. Barett, P. Erben, P. W. Manley, A. Hochhaus, A. Neubauer, and A. Burchert Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation Blood, March 1, 2007; 109(5): 2147 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes Important Therapeutic Targets in Chronic Myelogenous Leukemia Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Lerma, V.-A. Nguyen, T. Wang, A. Tipping, J. V. Melo, D. Kufe, D. J. Austin, and A. Deisseroth Novel compounds with antiproliferative activity against imatinib-resistant cell lines Mol. Cancer Ther., February 1, 2007; 6(2): 655 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, D. Jones, C. Nicaise, S. O'Brien, F. Giles, M. Talpaz, and J. Cortes Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure Blood, January 15, 2007; 109(2): 497 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Thomas Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges Hematology, January 1, 2007; 2007(1): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yokota, S. Kimura, S. Masuda, E. Ashihara, J. Kuroda, K. Sato, Y. Kamitsuji, E. Kawata, Y. Deguchi, Y. Urasaki, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood, January 1, 2007; 109(1): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Ann Intern Med, December 19, 2006; 145(12): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure Clin. Cancer Res., December 1, 2006; 12(23): 7180 - 7186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Puttini, A. M. L. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A. Donella-Deana, S. Ahmed, S. Redaelli, R. Piazza, V. Magistroni, et al. In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells Cancer Res., December 1, 2006; 66(23): 11314 - 11322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chen, V. Gandhi, and W. Plunkett A Sequential Blockade Strategy for the Design of Combination Therapies to Overcome Oncogene Addiction in Chronic Myelogenous Leukemia. Cancer Res., November 15, 2006; 66(22): 10959 - 10966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hu, S. Swerdlow, T. M. Duffy, R. Weinmann, F. Y. Lee, and S. Li Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice PNAS, November 7, 2006; 103(45): 16870 - 16875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Meyn III, M. B. Wilson, F. A. Abdi, N. Fahey, A. P. Schiavone, J. Wu, J. M. Hochrein, J. R. Engen, and T. E. Smithgall Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity J. Biol. Chem., October 13, 2006; 281(41): 30907 - 30916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrari-Amorotti, K. Keeshan, M. Zattoni, C. Guerzoni, G. Iotti, S. Cattelani, N. J. Donato, and B. Calabretta Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP{alpha} Blood, August 15, 2006; 108(4): 1353 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Quintas-Cardama and J. E. Cortes Chronic Myeloid Leukemia: Diagnosis and Treatment Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Tokarski, J. A. Newitt, C. Y. J. Chang, J. D. Cheng, M. Wittekind, S. E. Kiefer, K. Kish, F. Y.F. Lee, R. Borzillerri, L. J. Lombardo, et al. The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants Cancer Res., June 1, 2006; 66(11): 5790 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford, and T. L. Holyoake Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood, June 1, 2006; 107(11): 4532 - 4539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mishra, B. Zhang, J. M. Cunnick, N. Heisterkamp, and J. Groffen Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res., May 15, 2006; 66(10): 5387 - 5393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chandra, J. Tracy, D. Loegering, K. Flatten, S. Verstovsek, M. Beran, M. Gorre, Z. Estrov, N. Donato, M. Talpaz, et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance Blood, March 15, 2006; 107(6): 2501 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Trevino, J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model Am. J. Pathol., March 1, 2006; 168(3): 962 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Summy and G. E. Gallick Treatment for Advanced Tumors: Src Reclaims Center Stage Clin. Cancer Res., March 1, 2006; 12(5): 1398 - 1401. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Mauro Defining and Managing Imatinib Resistance Hematology, January 1, 2006; 2006(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kimura, H. Naito, H. Segawa, J. Kuroda, T. Yuasa, K. Sato, A. Yokota, Y. Kamitsuji, E. Kawata, E. Ashihara, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood, December 1, 2005; 106(12): 3948 - 3954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, Y. Hu, S. Swerdlow, T. M. Duffy, R. Weinmann, and F. Y. Lee Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1990 - 1990. [Abstract]
|
|
|
|
|
|
T. O'Hare, D. K. Walters, E. P. Stoffregen, T. Jia, P. W. Manley, J. Mestan, S. W. Cowan-Jacob, F. Y. Lee, M. C. Heinrich, M. W.N. Deininger, et al. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants Cancer Res., June 1, 2005; 65(11): 4500 - 4505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Prakash, O. R. Swamy, X. Peng, Z.-Y. Tang, L. Li, J. E. Larson, J. C. Cohen, J. Gill, G. Farr, S. Wang, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis Blood, May 15, 2005; 105(10): 3987 - 3994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia Blood, May 15, 2005; 105(10): 3995 - 4003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gu, L. Santiago, and B. S. Mitchell Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl Blood, April 15, 2005; 105(8): 3270 - 3277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Burgess, B. J. Skaggs, N. P. Shah, F. Y. Lee, and C. L. Sawyers Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance PNAS, March 1, 2005; 102(9): 3395 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gumireddy, S. J. Baker, S. C. Cosenza, P. John, A. D. Kang, K. A. Robell, M. V. R. Reddy, and E. P. Reddy A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance PNAS, February 8, 2005; 102(6): 1992 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Shah Loss of Response to Imatinib: Mechanisms and Management Hematology, January 1, 2005; 2005(1): 183 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Ilaria Jr. Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues Hematology, January 1, 2005; 2005(1): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, R. Pollock, E. P. Stoffregen, J. A. Keats, O. M. Abdullah, E. M. Moseson, V. M. Rivera, H. Tang, C. A. Metcalf III, R. S. Bohacek, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML Blood, October 15, 2004; 104(8): 2532 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, M. Rahmani, S. J. Corey, P. Dent, and S. Grant A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2 J. Biol. Chem., August 13, 2004; 279(33): 34227 - 34239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Legros, C. Bourcier, A. Jacquel, F.-X. Mahon, J.-P. Cassuto, P. Auberger, and G. Pages Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia Blood, July 15, 2004; 104(2): 495 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, M. Rahmani, X.-Y. Pei, P. Dent, and S. Grant Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms Blood, July 15, 2004; 104(2): 509 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Parmar, E. Katsoulidis, A. Verma, Y. Li, A. Sassano, L. Lal, B. Majchrzak, F. Ravandi, M. S. Tallman, E. N. Fish, et al. Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells J. Biol. Chem., June 11, 2004; 279(24): 25345 - 25352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grant and P. Dent Kinase Inhibitors and Cytotoxic Drug Resistance Clin. Cancer Res., April 1, 2004; 10(7): 2205 - 2207. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Donato, J. Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B. Aggarwal, S. Shishodin, M. Albitar, K. Hayes, H. Kantarjian, et al. Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia Cancer Res., January 15, 2004; 64(2): 672 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Ferrao, M. J. Frost, S.-P. Siah, and L. K. Ashman Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro Blood, December 15, 2003; 102(13): 4499 - 4503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Kirschner and K. Baltensperger Erythropoietin Promotes Resistance Against the Abl Tyrosine Kinase Inhibitor Imatinib (STI571) in K562 Human Leukemia Cells Mol. Cancer Res., November 1, 2003; 1(13): 970 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ly, A. F. Arechiga, J. V. Melo, C. M. Walsh, and S. T. Ong Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S6 and 4E-BP1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin Cancer Res., September 15, 2003; 63(18): 5716 - 5722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, et al. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells Cancer Res., August 15, 2003; 63(16): 5126 - 5135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-actin on the same membrane.
B, Jak kinases, Stat proteins (Stat 1, 3, or 5),
phosphatidylinositol-3'-kinase, or Akt phosphorylation (data not shown)
in LYN signaling in K562-R cells. LYN-mediated phosphorylation of
BCR-ABL itself (as recently reported for the closely related HCK
kinase; Schindler et al
new therapeutic principles.
J Intern Med.
2001;250:3-19